Nyrada Inc.: Advancing Neuro-Cardioprotection Through Innovative Drug Development

Nyrada Inc.(ASX: NYR) Advancing Neuro-Cardioprotection Through Innovative Drug Development Nyrada Inc. is an innovative biotech firm focused on developing small-molecule treatments that target TRPC ion channels. Its leading candidate, NYR-BI03, has shown encouraging potential for protecting both brain and heart tissue. The company is presently running a Phase I clinical trial that is randomized, double-blind, and placebo-controlled, aiming to evaluate how safe and well-tolerated NYR-BI03 is, along with how it behaves in the body of healthy volunteers. With no safety concerns reported by the Safety Review Committee, the trial has progressed to its third dosing cohort. Preclinical studies have demonstrated NYR-BI03’s efficacy in significantly reducing brain damage post-stroke, mitigating heart tissue damage following myocardial injury, and offering protection in traumatic brain injury scenarios. Collaborations with UNSW Sydney and the Walter Reed Army Institute of Research further reinforce the scientific credibility behind its research. With trial completion targeted for Q3 2025, Nyrada is well-positioned to make impactful strides in neuro-cardiovascular treatment innovation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com